RxDoctor Payments Data

Amy Malone, PA

Surgical · Longview, TXNPI 1063412468

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,598 of the $8,632 with a category attached, or 88.0%. It is spread thinly across 49 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,632in general payments, 2019–2025

Across 284 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$1K
  • AstraZeneca$840
  • GSK$644
  • Johnson & Johnson$572
  • Lilly USA, LLC$472
  • AbbVie$471
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,59888%
  • Education$1,03312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,632 in reported general payments places this provider in the 95th percentile of 804 surgical providers in Texas.

See all surgical providers in Texas

Medicare billing

Part B allowed, 2024
$89,839
Medicare patients
302
Services billed
3,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$21,529
Potassium Chloride140$1,780
Letrozole32$768
Ondansetron Hcl90$740
Dexamethasone41$601
Gabapentin44$574
Levothyroxine Sodium56$555
Mirtazapine30$503
Lidocaine-PrilocaineLidocaine/Prilocaine26$422
Lidocaine Hcl ViscousLidocaine Hcl17$375
Acetaminophen-CodeineAcetaminophen With Codeine24$270
Warfarin Sodium24$254
Promethazine Hcl45$253
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$213
Folic Acid12$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$209$21,52937 claims
Lilly USA, LLCOlanzapine$472$10323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 surgical providers in Texas.

Other surgical in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →